IL12RB1 and neoplasm: To address dose-limiting toxicity, we treated tumor-bearing mice with variants of IL-2 and IL-12 that were skewed toward T cells expressing CD25 and interleukin 12 receptor subunit beta 1 (Il12rb1), respectively (15, 16).